Your browser doesn't support javascript.
loading
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
Oran, Betül; Garcia-Manero, Guillermo; Saliba, Rima M; Alfayez, Mansour; Al-Atrash, Gheath; Ciurea, Stefan O; Jabbour, Elias J; Mehta, Rohtesh S; Popat, Uday R; Ravandi, Farhad; Alousi, Amin M; Kadia, Tapan M; Konopleva, Marina; DiNardo, Courtney D; Rezvani, Katy; Shpall, Elizabeth J; Sharma, Padmanee; Kantarjian, Hagop M; Champlin, Richard E; Daver, Naval.
Afiliação
  • Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Saliba RM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alfayez M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Al-Atrash G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ciurea SO; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mehta RS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Popat UR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alousi AM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rezvani K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shpall EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 126(10): 2193-2205, 2020 05 15.
Article em En | MEDLINE | ID: mdl-32125707
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Ciclofosfamida / Inibidores de Checkpoint Imunológico / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Ciclofosfamida / Inibidores de Checkpoint Imunológico / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2020 Tipo de documento: Article